<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02766673</url>
  </required_header>
  <id_info>
    <org_study_id>15-012264</org_study_id>
    <nct_id>NCT02766673</nct_id>
  </id_info>
  <brief_title>Aerosolized Albuterol Use in Severe BPD</brief_title>
  <official_title>Safety and Efficacy of Aerosolized Albuterol in Mechanically Ventilated Infants With Bronchopulmonary Dysplasia (BDP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital of Philadelphia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently several dose schedules of Albuterol are administered via nebulization to infants in
      the neonatal and infant intensive care unit (N/IICU). As Albuterol is not FDA approved for
      this population (under 2 years) there is no standard recommended dose. Aerosolized Albuterol
      is one of the most widely used therapies that are utilized for infants with chronic lung
      disease. The common practice in the N/IICU is weight base dosing of all medications. This
      contradicts the aerosol science recommendations, which advise not to titrate doses by weight
      as the patient naturally self-regulates their dose according to the change in minute
      ventilation with age. In addition, the wide use of aerosolized Albuterol in the infant with
      Bronchopulmonary Dysplasia (BPD) has little current evidence of efficacy in this disease.
      Understanding the appropriate dose for effective treatment as well as the indication for use
      in the BPD population would provide the clinician with useful guidelines.

      The investigators propose to analyze the safety and efficacy of aerosolized albuterol in
      infants with BPD comparing the recommended dose per aerosolization literature with the common
      dosing practices at The Children's Hospital of Philadelphia (CHOP) as well as placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, blinded cross-over study of infants with a diagnosis of Severe BPD that
      are mechanically ventilated. Participants will receive 3 sets of treatment (2.5mg Albuterol,
      1.25mg Albuterol, 3ml normal saline placebo), in random order. Each treatment will be
      administered every 4 hours for 24 hours. After a 6 hour washout phase, the next group of
      interventions will be applied. Following another wash-out phase, the final group of
      intervention will be applied. Pulmonary mechanics from the ventilator (e.g. airway
      compliance, airway resistance, tidal volume, peak inspiratory pressure, Forced Expiratory
      Flow at 75% of forced vital capacity, etc.) and the patient short term response to therapy
      (heart rate, blood pressure, heart rhythm) will be assessed for the duration of the treatment
      period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Actual">June 2018</completion_date>
  <primary_completion_date type="Actual">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Expiratory Flow Between Pre and Post-medication Dosing</measure>
    <time_frame>every 4 hours in each treatment group, up to 24 hours</time_frame>
    <description>Expiratory flow at 75% of vital capacity (EF75) will be measured before beginning each treatment and again 15-30 min after each treatment phase. Therefore there will be 6 pairs (12) of EF values to determine the change in EF for each treatment. this measure is done by measuring the expiratory flow at 75% of exhalation on as measure on the flow volume loop of the ventilator. a single mechanical breath is chosen and the flow volume loop is frozen on the ventilator screen. the clinician can then scroll to measure total tidal volume for the breath, then multiple this volume by 0.25 (to ascertain the volume that the time point of 75% of exhalation), then scroll along the expiratory side of the flow volume loop until the calculated volume is reached and then the flow at that time point is recorded.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Heart Rate (Beats/Min) Between Pre and Post-medication Dosing</measure>
    <time_frame>every 4 hours in each treatment group, up to 24 hours</time_frame>
    <description>Heart rate will be measured before beginning each treatment and again 15-30 min after the conclusion of each treatment phase (4 hours). Therefore there will be 6 pairs of heart rates (12 measures), to determine the change in HR for each treatment group.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Severe Bronchopulmonary Dysplasia</condition>
  <arm_group>
    <arm_group_label>Full Dose Albuterol Sulfate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2.5mg of Albuterol Sulfate will be administered via nebulizer and mechanical ventilator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Half Dose Albuterol Sulfate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.25mg of Albuterol Sulfate will be administered via nebulizer and mechanical ventilator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sterile Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3ml of 0.9% sterile saline will be administered via nebulizer and mechanical ventilator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albuterol Sulfate</intervention_name>
    <description>Subjects will receive a dose of study medication every 4 hours for 24 total hours</description>
    <arm_group_label>Full Dose Albuterol Sulfate</arm_group_label>
    <arm_group_label>Half Dose Albuterol Sulfate</arm_group_label>
    <other_name>Salbutamol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sterile Saline</intervention_name>
    <description>Subjects will receive a dose of study medication every 4 hours for 24 total hours</description>
    <arm_group_label>Sterile Saline</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Infants greater than or equal to 36 weeks corrected gestational age to one year of age

          2. Diagnosis of BPD in accordance with The Eunice Kennedy Shriver National Institute of
             Child Health and Human Development (NICHD) definition

          3. May have a current order for short acting bronchodilator, not required

          4. May have congenital anomalies unless one or more of the exclusion criteria are met,
             not required

          5. Receiving conventional mechanical ventilation via an artificial airway (endotracheal
             tube or tracheostomy) via Draeger V500 Ventilator

          6. Parental/guardian permission (informed consent)

        Exclusion Criteria:

          1. Airway leak greater than 10%

          2. Unilateral lung disease

          3. Current order for inhaled anticholinergic (i.e. ipratropium bromide)

          4. Active pulmonary or systemic infection

          5. Scheduled order for other medication that cause bronchodilation (i.e. atrovent,
             magnesium sulfate, ketamine, etc.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Year</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin Dysart, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>May 9, 2016</study_first_submitted>
  <study_first_submitted_qc>May 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2016</study_first_posted>
  <results_first_submitted>April 22, 2019</results_first_submitted>
  <results_first_submitted_qc>July 5, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 30, 2019</results_first_posted>
  <last_update_submitted>August 15, 2019</last_update_submitted>
  <last_update_submitted_qc>August 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchopulmonary Dysplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 23, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/73/NCT02766673/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The original study sample size called for 25 subjects. The block randomization scheme of 6 treatment sequences within 1 randomization block. Therefore we recruited 24 patients to complete 4 randomization block. the 25th patient would have started a new randomization block and make one treatment sequence more common that the others.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment Sequence A</title>
          <description>Treatment group 1: Placebo (0.9% sterile saline) every 4 hours for 24 hours
6 hour washout phase
Treatment group 2: 1.25mg Albuterol every 4 hours for 24 hours
6 hour washout phase
Treatment group 3: 2.5 mg Albuterol every 4 hours for 24 hours</description>
        </group>
        <group group_id="P2">
          <title>Treatment Sequence B</title>
          <description>Treatment group 1: Placebo (0.9% sterile saline) every 4 hours for 24 hours
6 hour washout phase
Treatment group 2: 2.5mg Albuterol every 4 hours for 24 hours
6 hour washout phase
Treatment group 3: 1.25mg Albuterol every 4 hours for 24 hours</description>
        </group>
        <group group_id="P3">
          <title>Treatment Sequence C</title>
          <description>Treatment Group 1: 1.25 mg Albuterol every 4 hours for 24 hours
6 hour washout phase
Treatment group 2: Placebo (0.9% sterile saline) every 4 hours for 24 hours
6 hour washout phase
Treatment group 3: 2.5mg albuterol every 4 hours for 24 hours</description>
        </group>
        <group group_id="P4">
          <title>Treatment Sequence D</title>
          <description>Treatment Group 1: 1.25 mg Albuterol every 4 hours for 24 hours
6 hour washout phase
Treatment group 2: 2.5mg albuterol every 4 hours for 24 hours
6 hour washout phase
Treatment group 3: Placebo (0.9% sterile saline) every 4 hours for 24 hours</description>
        </group>
        <group group_id="P5">
          <title>Treatment Sequence E</title>
          <description>Treatment group 1: 2.5mg albuterol every 4 hours for 24 hours
6 hour washout phase
Treatment group 2: Placebo (0.9% sterile saline) every 4 hours for 24 hours
6 hour washout phase
Treatment Group 3: 1.25 mg Albuterol every 4 hours for 24 hours</description>
        </group>
        <group group_id="P6">
          <title>Treatment Sequence F</title>
          <description>Treatment group 1: 2.5mg albuterol every 4 hours for 24 hours
6 hour washout phase
Treatment Group 2: 1.25 mg Albuterol every 4 hours for 24 hours
6 hour washout phase
Treatment group 3: Placebo (0.9% sterile saline) every 4 hours for 24 hours</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall Study</title>
          <description>This was a crossover study therefore all patients were scheduled to receive all 3 treatment groups. Enrollment demographics will be the same for all groups.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="170.4" spread="49.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.7" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Birth Gestational Age</title>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Birth Weight</title>
          <units>g</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="611" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Corrected Gestational Age</title>
          <units>Weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Expiratory Flow Between Pre and Post-medication Dosing</title>
        <description>Expiratory flow at 75% of vital capacity (EF75) will be measured before beginning each treatment and again 15-30 min after each treatment phase. Therefore there will be 6 pairs (12) of EF values to determine the change in EF for each treatment. this measure is done by measuring the expiratory flow at 75% of exhalation on as measure on the flow volume loop of the ventilator. a single mechanical breath is chosen and the flow volume loop is frozen on the ventilator screen. the clinician can then scroll to measure total tidal volume for the breath, then multiple this volume by 0.25 (to ascertain the volume that the time point of 75% of exhalation), then scroll along the expiratory side of the flow volume loop until the calculated volume is reached and then the flow at that time point is recorded.</description>
        <time_frame>every 4 hours in each treatment group, up to 24 hours</time_frame>
        <population>Each subject had the potential for 6 paired observations (12 measures) per treatment group (comparison of measure before and after each dose of the study drug). 2 subjects did not complete all 3 treatment groups. Some measurements were missed leaving less than the total potential number of observations.</population>
        <group_list>
          <group group_id="O1">
            <title>Full Dose Albuterol Sulfate</title>
            <description>2.5mg of Albuterol Sulfate will be administered via nebulizer and mechanical ventilator
Albuterol Sulfate: Subjects will receive a dose of study medication every 4 hours for 24 total hours</description>
          </group>
          <group group_id="O2">
            <title>Half Dose Albuterol Sulfate</title>
            <description>1.25mg of Albuterol Sulfate will be administered via nebulizer and mechanical ventilator
Albuterol Sulfate: Subjects will receive a dose of study medication every 4 hours for 24 total hours</description>
          </group>
          <group group_id="O3">
            <title>Sterile Saline</title>
            <description>3ml of 0.9% sterile saline will be administered via nebulizer and mechanical ventilator
Sterile Saline: Subjects will receive a dose of study medication every 4 hours for 24 total hours</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Expiratory Flow Between Pre and Post-medication Dosing</title>
          <description>Expiratory flow at 75% of vital capacity (EF75) will be measured before beginning each treatment and again 15-30 min after each treatment phase. Therefore there will be 6 pairs (12) of EF values to determine the change in EF for each treatment. this measure is done by measuring the expiratory flow at 75% of exhalation on as measure on the flow volume loop of the ventilator. a single mechanical breath is chosen and the flow volume loop is frozen on the ventilator screen. the clinician can then scroll to measure total tidal volume for the breath, then multiple this volume by 0.25 (to ascertain the volume that the time point of 75% of exhalation), then scroll along the expiratory side of the flow volume loop until the calculated volume is reached and then the flow at that time point is recorded.</description>
          <population>Each subject had the potential for 6 paired observations (12 measures) per treatment group (comparison of measure before and after each dose of the study drug). 2 subjects did not complete all 3 treatment groups. Some measurements were missed leaving less than the total potential number of observations.</population>
          <units>L/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>EF 75% Observatrions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>EF 75% Observatrions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="141"/>
                <count group_id="O3" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.38" spread="2.3"/>
                    <measurement group_id="O2" value="0.70" spread="2.4"/>
                    <measurement group_id="O3" value="0.45" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Heart Rate (Beats/Min) Between Pre and Post-medication Dosing</title>
        <description>Heart rate will be measured before beginning each treatment and again 15-30 min after the conclusion of each treatment phase (4 hours). Therefore there will be 6 pairs of heart rates (12 measures), to determine the change in HR for each treatment group.</description>
        <time_frame>every 4 hours in each treatment group, up to 24 hours</time_frame>
        <population>There was a potential for up to 6 paired observations (12 measures) per treatment group. 2 patients did not complete all 3 treatment groups resulting is lower number of observations for the potential total.</population>
        <group_list>
          <group group_id="O1">
            <title>Full Dose Albuterol Sulfate</title>
            <description>2.5mg of Albuterol Sulfate will be administered via nebulizer and mechanical ventilator
Albuterol Sulfate: Subjects will receive a dose of study medication every 4 hours for 24 total hours</description>
          </group>
          <group group_id="O2">
            <title>Half Dose Albuterol Sulfate</title>
            <description>1.25mg of Albuterol Sulfate will be administered via nebulizer and mechanical ventilator
Albuterol Sulfate: Subjects will receive a dose of study medication every 4 hours for 24 total hours</description>
          </group>
          <group group_id="O3">
            <title>Sterile Saline</title>
            <description>3ml of 0.9% sterile saline will be administered via nebulizer and mechanical ventilator
Sterile Saline: Subjects will receive a dose of study medication every 4 hours for 24 total hours</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Heart Rate (Beats/Min) Between Pre and Post-medication Dosing</title>
          <description>Heart rate will be measured before beginning each treatment and again 15-30 min after the conclusion of each treatment phase (4 hours). Therefore there will be 6 pairs of heart rates (12 measures), to determine the change in HR for each treatment group.</description>
          <population>There was a potential for up to 6 paired observations (12 measures) per treatment group. 2 patients did not complete all 3 treatment groups resulting is lower number of observations for the potential total.</population>
          <units>% change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Heart Rate measurements beats/min</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Heart Rate measurements beats/min</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="144"/>
                <count group_id="O3" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.074" spread="0.129"/>
                    <measurement group_id="O2" value="0.031" spread="0.120"/>
                    <measurement group_id="O3" value="0.009" spread="0.084"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were continuously monitored for and were attributed to a given treatment group from the time that the first treatment was given through the washout phase following the given treatment group. Albuterol has an effect range for 4-6 hours so any adverse events from the medication. Time frame of monitoring for adverse events ended 6 hours after the final medication dose was administered.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Full Dose Albuterol</title>
          <description>2.5mg of Albuterol Sulfate will be administered via nebulizer and mechanical ventilator
Albuterol Sulfate: Subjects will receive a dose of study medication every 4 hours for 24 total hours</description>
        </group>
        <group group_id="E2">
          <title>Half Dose Albuterol</title>
          <description>1.25mg of Albuterol Sulfate will be administered via nebulizer and mechanical ventilator
Albuterol Sulfate: Subjects will receive a dose of study medication every 4 hours for 24 total hours</description>
        </group>
        <group group_id="E3">
          <title>Sterile Saline</title>
          <description>3ml of 0.9% sterile saline will be administered via nebulizer and mechanical ventilator
Sterile Saline: Subjects will receive a dose of study medication every 4 hours for 24 total hours</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Natalie Napolitano, MPH, RRT-NPS, FAARC</name_or_title>
      <organization>Children's Hospital of Philadelphia</organization>
      <phone>215-590-1708</phone>
      <email>napolitanon@email.chop.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

